Onconetix, Inc. Proceeds from Debt, Net of Issuance Costs
Onconetix, Inc. (ONCO) reported Proceeds from Debt, Net of Issuance Costs of $16.47 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2023-03-09
- Onconetix, Inc. proceeds from debt, net of issuance costs for fiscal 2022 was $16.47M.
| Period end | Proceeds from Debt, Net of Issuance Costs 1 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|
| 2022-12-31 | $16.47M 10-K · filed 2023-03-09 | |
| 2022-04-19 | $6.90M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |